Show simple item record

dc.contributor.authorHarcourt, Jonny P.
dc.contributor.authorLambert, Aileen
dc.contributor.authorWong, Phui Yee
dc.contributor.authorPatel, Mitesh
dc.contributor.authorAgarwal, Kiran
dc.contributor.authorGolding, John F.
dc.contributor.authorBronstein, Adolfo M.
dc.date.accessioned2019-01-03T15:08:48Z
dc.date.available2019-01-03T15:08:48Z
dc.date.issued2019-02-14
dc.identifier.citationHarcourt, J.P., Lambert, A., Wong, P.Y., Patel, M., Agarwal, K., Golding, J.F. and Bronstein, A.M. (2019) 'Long-term follow-up of intratympanic methylprednisolone versus gentamicin in patients with unilateral Menière’s disease', Otology & Neurotology. 40 (4), pp. 491-496. doi:10.1097/MAO.0000000000002108
dc.identifier.issn1531-7129en
dc.identifier.doi10.1097/MAO.0000000000002108
dc.identifier.urihttp://hdl.handle.net/2436/622005
dc.description.abstractObjectives: To determine whether long term (>48 months) symptomatic vertigo control is sustained in patients with Menière’s disease from a previous comparative trial of intratympanic methylprednisolone versus gentamicin, and if the two treatments remain nonsignificantly different at longterm follow-up. Study Design: Mail survey recording vertigo frequency in the previous one and six months, further intratympanic treatment received, and validated symptom questionnaires. Setting: Outpatient hospital clinic setting. Patients: Adult patients with definite unilateral refractory Menie`re’s disease, who previously received in tratympanic treatment in a comparative trial. Intervention: A survey of trial participants who received intratympanic gentamicin (40 mg/mL) or methylprednisolone (62.5 mg/mL). Outcome measures: Primary: number of vertigo attacks in the 6 months prior to receiving this survey compared with the 6 months before the first trial injection. Secondary: : Number of vertigo attacks over the previous 1 month; validated symptom questionnaire scores of tinnitus, dizziness, vertigo, aural fullness, and functional disability. Results: Average follow-up was 70.8 months (standard deviation 17.0) from the first treatment injection. Vertigo attacks in the 6 months prior to receiving the current survey reduced by 95% compared to baseline in both drug groups (intention-to-treat analysis, both p<0.001). No significant difference between drugs was found for the primary and secondary outcomes. Eight participants (methylprednisolone ¼ 5 and gentamicin ¼ 3) required further injections for relapse after completing the original trial. Conclusion: Intratympanic methylprednisolone treatment provides effective long-lasting relief of vertigo, without the known inner-ear toxicity associated with gentamicin. There are no significant differences between the two treatments at long term follow-up.en
dc.formatapplication/PDFen
dc.language.isoenen
dc.publisherLippincott Williams & Wilkinsen
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectclinical trialen
dc.subjectdizzinessen
dc.subjectintratympanic methylprednisoloneen
dc.subjectintratympanic gentamicinen
dc.subjectintratympanic steroiden
dc.subjectmeniere's diseaseen
dc.subjectneurotologyen
dc.subjectototoxicityen
dc.subjecttinnitusen
dc.subjectvertigoen
dc.subjectvestibular diseaseen
dc.titleLong-term follow-up of intratympanic methylprednisolone versus gentamicin in patients with unilateral Menière’s diseaseen
dc.typeJournal article
dc.identifier.journalOtology & Neurotologyen
dc.date.accepted2018-11-13
rioxxterms.funderUniversity of Wolverhamptonen
rioxxterms.identifier.projectUOW030119MPen
rioxxterms.versionAMen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2019-02-14en
dc.source.volume40
dc.source.issue4
dc.source.beginpage491
dc.source.endpage496
refterms.dateFCD2019-01-03T15:08:48Z
refterms.versionFCDAM


Files in this item

Thumbnail
Name:
Harcourt Long term follow up of ...
Size:
443.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States